Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥60 years in Japan, Korea, and Taiwan
jRCT2051210030Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (4 arms), sponsored by Pfizer. Started Jun 2021; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2051210030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210030.